Last $3.15 USD
Change Today +0.04 / 1.29%
Volume 82.9K
NEO On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 5:20 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

neogenomics inc (NEO) Snapshot

Open
$3.09
Previous Close
$3.11
Day High
$3.21
Day Low
$3.03
52 Week High
01/13/14 - $4.69
52 Week Low
08/19/13 - $2.05
Market Cap
154.7M
Average Volume 10 Days
225.4K
EPS TTM
$0.05
Shares Outstanding
49.1M
EX-Date
--
P/E TM
63.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOGENOMICS INC (NEO)

Related News

No related news articles were found.

neogenomics inc (NEO) Related Businessweek News

No Related Businessweek News Found

neogenomics inc (NEO) Details

NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to identify cell proteins in a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

315 Employees
Last Reported Date: 02/24/14
Founded in 2001

neogenomics inc (NEO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $613.0K
Chief Medical Officer and Director of Researc...
Total Annual Compensation: $98.8K
Chief Scientific Officer
Total Annual Compensation: $351.9K
Compensation as of Fiscal Year 2012.

neogenomics inc (NEO) Key Developments

Neogenomics Inc. Announces Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome

NeoGenomics Inc. announced that it has validated and launched the first two of a series of next generation cancer profiling tests. These tests are designed for profiling myelodysplastic syndrome and solid tumor cancers. Additional cancer-type specific next generation tests are currently being validated and are scheduled for launch over the next several months. The MDS next generation sequencing test can be performed on bone marrow, peripheral blood and plasma samples. Plasma-based testing for MDS may be used to avoid bone marrow biopsies. It also has the potential to quantify and monitor tumor load and to detect the emergence of subclones. The MDS next generation profiling test covers 16 genes involved in the various pathways of MDS, including epigenomics, signal transduction, transcription regulation and spliceosomes. This test is particularly important for confirming and defining the diagnosis of MDS, which can be extremely difficult in early stages of the disease. The solid tumor cancer NGS profiling test covers 48 genes and is performed on paraffin-embedded tissue. This solid tumor profile is extensive and covers the driver genes involved in various types of solid tumor cancers.

Neogenomics Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for the First Quarter and Full Year of Fiscal 2014

Neogenomics Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported net revenue of $18.323 million compared to $14.893 million a year ago. Income from operations was $1.204 million compared to loss from operations of $0.196 million a year ago. Income before taxes was $0.963 million compared to loss before taxes of $0.113 million a year ago. Net income was $0.857 million or $0.02 basic and diluted EPS compared to net loss of $0.113 million a year ago. EBITDA was $2.334 million compared to $1.341 million a year ago. Adjusted EBITDA was $2.733 million compared to $1.440 million a year ago. For the full year, the company reported net revenue of $66.467 million compared to $59.867 million a year ago. Income from operations was $3.174 million compared to $1.211 million a year ago. Income before taxes was $2.185 million compared to $0.065 million a year ago. Net income was $2.033 million or $0.04 basic and diluted EPS compared to $0.065 million a year ago. Net cash provided by operating activities was $2.227 million compared to net cash used in operating activities of $0.492 million a year ago. EBITDA was $7.586 million compared to $5.030 million a year ago. Adjusted EBITDA was $8.515 million compared to $5.998 million a year ago. Revenue growth was driven by an expanded menu of tests and an increasing client base. The company expects revenue of $73 - $77 million and net income of $0.05 - $0.07 per share in fiscal year of 2014. For the fiscal first quarter of 2014, the company expects revenue of $18.8 - $19.3 million and net income of $0.01-$0.02 per share.

Neogenomics Mulls Acquisitions

Neogenomics Inc. (NasdaqCM:NEO) plans to make acquisitions. Douglas M. VanOort, Chairman and Chief Executive Officer of Neogenomics, said, “We are increasingly focused on exploring mergers and/or acquisitions as a means to increase our scale and to diversify our portfolio.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEO:US $3.15 USD +0.04

NEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Labs Inc $27.20 USD -0.19
Cancer Genetics Inc $15.34 USD +0.045
Foundation Medicine Inc $26.54 USD -0.64
Genomic Health Inc $26.81 USD -0.02
Response Genetics Inc $1.16 USD -0.03
View Industry Companies
 

Industry Analysis

NEO

Industry Average

Valuation NEO Industry Range
Price/Earnings 80.7x
Price/Sales 2.3x
Price/Book 7.0x
Price/Cash Flow 75.1x
TEV/Sales 2.1x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGENOMICS INC, please visit www.neogenomics.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.